Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.
This study has been withdrawn prior to recruitment.
( This study was withdrawn due to business reasons. )
Study NCT00562055 Information provided by Pfizer
First Received: November 19, 2007 Last Updated: June 19, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Attention Deficit Disorder with Hyperactivity
Disease
Hyperkinesis
More general conditions related to this trial
Attention Deficit and Disruptive Behavior Disorders
Dyskinesias
Mental Disorders
Mental Disorders Diagnosed in Childhood
Nervous System Diseases
Neurologic Manifestations
Pathologic Processes
Signs and Symptoms
Interventions listed in this trial
Atomoxetine
PNU-165442G; [S,S]-reboxetine
Additional drug interventions recognized in this trial
Reboxetine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Uptake Inhibitors
Antidepressive Agents
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Sponsors listed in this trial
Pfizer
Back to top of Main Content
